Asymchem Laboratories (Tianjin) Co., Ltd. (ASLTY)

Market Cap	7.90B +69.6%
Revenue (ttm)	1.11B +18.1%
Net Income	176.59M +14.0%
EPS	0.25 +17.0%
Shares Out	n/a
PE Ratio	32.49
Forward PE	30.43
Dividend	0.10 (1.17%)
Ex-Dividend Date	Jun 26, 2026

Volume	100
Open	8.15
Previous Close	7.45
Day's Range	8.15 - 8.15
52-Week Range	5.00 - 8.15
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 22, 2026

About ASLTY

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in ke...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 10,617
• Stock Exchange: OTCMKTS
• Ticker Symbol: ASLTY

Financial Performance

In 2025, ASLTY's revenue was 6.67 billion, an increase of 14.91% compared to the previous year's 5.80 billion. Earnings were 1.13 billion, an increase of 19.35%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error